BerGenBio

Regulatory Filings • Oct 7, 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Ph1b data support safety, predictable PK and adequate plasma exposure

Bergen, Norway, October 7, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announced today preliminary safety data from the

Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung

Cancer (NSCLC) patients.

The Phase 1b part of the study evaluated three escalating doses of BerGenBio's

selective AXL inhibitor bemcentinib in combination with standard chemo

-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda ®, for

the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was

the assessment of the safety profile of the combination in NSCLC patients

regardless of their STK11 mutational status.

Key conclusions include:

· All three selected doses demonstrated that the triplet combination is well

tolerated with no new safety signals identified, supporting the further clinical

development of bemcentinib and CIT in 1L NSCLC patients.

· No dose-related impact on electrocardiographic changes (QTc), a known class

effect of tyrosine kinase inhibitors, was reported for bemcentinib during the

observation period.

· Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib,

achieving levels consistent with that previously observed in responders in

BerGenBio's BGBC008 study of bemcentinib and pembrolizumab in second-line NSCLC

patients.

Martin Olin, Chief Executive Officer of BerGenBio, commented: "The data show

that bemcentinib has a manageable safety profile and gives us increased

confidence in continuing the BGBC016 clinical trial. The global trial is

currently enrolling patients in Phase 2a targeting patients with a mutation in

the STK11 gene, and we look forward to sharing the first preliminary data as

they mature."

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About STK11m NSCLC

Patients with STK11m NSCLC have a significantly poorer response to current

therapies, including immune checkpoint inhibitors, when compared with patients

with wild-type (non-mutated) STK11. AXL plays a significant role in the survival

and spread of cancer and STK11m NSCLC patients have a high expression of AXL

suggesting that AXL is an important target to prevent disease progression and

resistance to existing therapies. Bemcentinib's selective inhibition of AXL has

been shown to improve the response to immune checkpoint inhibition in STK11m

patient-derived preclinical models and in early clinical studies.  There are

currently no targeted therapies available for the STK11m NSCLC patient

population, which represents up to 20% of 1L NSCLC patients.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visitwww.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.